On the 5th, Professor Kiho Han’s team from the Department of Nano Convergence Engineering at Inje University and Professor Jaeseung Jeong’s team from the Department of Urology at Haeundae Paik Hospital developed a technology to separate cancer cells from the blood of prostate cancer patients using micro nanotechnology. They also developed a multi-gene model based on blood tumor cells that can provide precise diagnosis and treatment policies for metastatic prostate cancer patients.
In modern medicine, prostate biopsy is required to diagnose prostate cancer. Imaging tests such as CT and MRI are essential to confirm metastatic prostate cancer. A technology has been developed that can diagnose metastatic prostate cancer through simple blood tests without such an imaging test.
Until now, there has been a problem that access is difficult as the cost for cancer tissue-based tests for periodic prognosis observation of individual cancer patients and for subsequent genetic tests increases. Professor Han’s team and Professor Jeong’s team presented a method of diagnosing and predicting the prognosis of metastatic prostate cancer patients through non-invasive blood tumor cell isolation showing the genetic characteristics of cancer patients.
Prostate-specific gene markers (AR, AR-V7, PSA, PSMA) and epithelial cell selection gene markers were detected by grafting digital polymerase chain reaction technology based on micro-droplets with high gene detection in addition to precise blood cancer cell isolation. In addition, by combining these, a mathematical model capable of diagnosing and predicting the prognosis of more than 90% of patients with metastatic prostate cancer was confirmed. By simultaneously showing the trend of increasing the number of cancer cells in the blood and the amount of gene expression in proportion to the level of the prostate antigen test, we drew important results showing that precise diagnosis is possible for each patient.
Professor Jeong Jae-seung said, “The research on blood cancer cells in the field of precision medicine continues to attract attention.” “Through this study, it will be possible to contribute not only to the treatment direction for prostate cancer patients, but also to the development of basic medicine. ”
This research was conducted through the support of the Ministry of Science, ICT, and Korea Research Foundation’s personal basic research (first innovation laboratory) and mid-level research projects, and was published in the February 2021 issue of the Japan Cancer Society official journal (Cancer Science). .
Reporter Kim Tae-hyun [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution